Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2013 1
2017 2
2018 1
2021 1
2022 3
2023 1
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

11 results

Results by year

Filters applied: . Clear all
Your search was processed without automatic term mapping because it retrieved zero results.
Page 1
Conflict of Interest Disclosures.
[No authors listed] [No authors listed] Global Spine J. 2023 May;13(2_suppl):568S-591S. doi: 10.1177/21925682231173597. Global Spine J. 2023. PMID: 37222100 Free PMC article. No abstract available.
Conflict of Interest Disclosures.
[No authors listed] [No authors listed] Global Spine J. 2024 May;14(4_suppl):690S-714S. doi: 10.1177/21925682241245615. Global Spine J. 2024. PMID: 38726630 Free PMC article. No abstract available.
Engineering a synthesis-friendly serum responsive promoter for antibiotic selection of genomic integration in cell-based therapy.
Lam CKC, Truong K. Lam CKC, et al. Biotechnol Lett. 2022 Apr;44(4):605-611. doi: 10.1007/s10529-022-03244-z. Epub 2022 Mar 16. Biotechnol Lett. 2022. PMID: 35294696
For clinical cell-based therapies (e.g. CAR-T cells), the genomic integration of therapeutic genes into cells are selected using inefficient resistance genes of host origin to avoid potential immune response from using more efficient resistance genes of foreign origin. ... …
For clinical cell-based therapies (e.g. CAR-T cells), the genomic integration of therapeutic genes into cells are selected using inef …
AD Informer Set: Chemical tools to facilitate Alzheimer's disease drug discovery.
Potjewyd FM, Annor-Gyamfi JK, Aubé J, Chu S, Conlon IL, Frankowski KJ, Guduru SKR, Hardy BP, Hopkins MD, Kinoshita C, Kireev DB, Mason ER, Moerk CT, Nwogbo F, Pearce KH, Richardson TI, Rogers DA, Soni DM, Stashko M, Wang X, Wells C, Willson TM, Frye SV, Young JE, Axtman AD. Potjewyd FM, et al. Alzheimers Dement (N Y). 2022 Apr 20;8(1):e12246. doi: 10.1002/trc2.12246. eCollection 2022. Alzheimers Dement (N Y). 2022. PMID: 35475262 Free PMC article.
Nursing-led Home Visits Post-hospitalization for Children with Medical Complexity.
Wells S, O'Neill M, Rogers J, Blaine K, Hoffman A, McBride S, Tschudy MM, Shumskiy I, Mauskar S, Berry JG. Wells S, et al. J Pediatr Nurs. 2017 May-Jun;34:10-16. doi: 10.1016/j.pedn.2017.03.003. Epub 2017 Mar 23. J Pediatr Nurs. 2017. PMID: 28342694
Of the 147 problems identified, 26.5% (n=39) pertained to social/family issues (e.g., financial instability), 23.8% (n=35) medications (e.g., wrong dose), 20.4% (n=30) durable medical equipment (e.g., insufficient supply or faulty function), 20.4% (n=30) chil …
Of the 147 problems identified, 26.5% (n=39) pertained to social/family issues (e.g., financial instability), 23.8% (n=35) medication …
Generation of stable cell lines using readthrough expression from lentiviral integration.
Jadav A, Truong K. Jadav A, et al. Biotechnol Lett. 2021 Nov;43(11):2131-2136. doi: 10.1007/s10529-021-03186-y. Epub 2021 Sep 17. Biotechnol Lett. 2021. PMID: 34533680
Therefore, we suggest that the mechanism of readthrough expression may have further applications in the expression of larger genes or genetic circuits (e.g. cell-based therapeutics), where the lentiviral cargo limit is stretched to the maximum....
Therefore, we suggest that the mechanism of readthrough expression may have further applications in the expression of larger genes or geneti …
Engineered Proteins Program Mammalian Cells to Target Inflammatory Disease Sites.
Qudrat A, Mosabbir AA, Truong K. Qudrat A, et al. Cell Chem Biol. 2017 Jun 22;24(6):703-711.e2. doi: 10.1016/j.chembiol.2017.05.008. Epub 2017 May 25. Cell Chem Biol. 2017. PMID: 28552580 Free article.
Disease sites in atherosclerosis and cancer feature cell masses (e.g., plaques/tumors), a low pH extracellular microenvironment, and various pro-inflammatory cytokines such as tumor necrosis factor alpha (TNFalpha). ...
Disease sites in atherosclerosis and cancer feature cell masses (e.g., plaques/tumors), a low pH extracellular microenvironment, and …
A monoclonal antibody acts as a migratory cue via Ca2+ re-wiring.
Mosabbir AA, Qudrat A, Truong K. Mosabbir AA, et al. Integr Biol (Camb). 2018 Mar 1;10(3):166-173. doi: 10.1039/c7ib00203c. Epub 2018 Mar 5. Integr Biol (Camb). 2018. PMID: 29504002
In particular, the dimerization of the vascular endothelial growth factor (VEGF) receptor 2 (VEGFR2) stimulates early events occurring within minutes (e.g. Ca(2+) signal generation) and late events occurring over hours and days (e.g. cell migration in angiogenesis). …
In particular, the dimerization of the vascular endothelial growth factor (VEGF) receptor 2 (VEGFR2) stimulates early events occurring withi …
Use of AD Informer Set compounds to explore validity of novel targets in Alzheimer's disease pathology.
Potjewyd FM, Annor-Gyamfi JK, Aubé J, Chu S, Conlon IL, Frankowski KJ, Guduru SKR, Hardy BP, Hopkins MD, Kinoshita C, Kireev DB, Mason ER, Moerk CT, Nwogbo F, Pearce KH Jr, Richardson TI, Rogers DA, Soni DM, Stashko M, Wang X, Wells C, Willson TM, Frye SV, Young JE, Axtman AD. Potjewyd FM, et al. Alzheimers Dement (N Y). 2022 Apr 12;8(1):e12253. doi: 10.1002/trc2.12253. eCollection 2022. Alzheimers Dement (N Y). 2022. PMID: 35434254 Free PMC article.
Current Perceptions, Practice Patterns, and Barriers to Adoption of Transperineal Prostate Biopsy under local anesthesia.
Bulusu A, Ferrante S, Wu RC, Qi J, Montie J, Ginsburg KB, Semerjian A, Raman JD, Ginzburg S, Patel A, Rogers CG, George VK, Stork B, George AK; Michigan Urological Surgery Improvement Collaborative. Bulusu A, et al. Urology. 2024 Apr 26:S0090-4295(24)00292-9. doi: 10.1016/j.urology.2024.04.019. Online ahead of print. Urology. 2024. PMID: 38679295
11 results